Iovance announced multiple updates in conjunction with online abstracts made available ahead of presentations at the 2019 American Society of Clinical Oncology, or ASCO, annual meeting May 31-June 4, in Chicago.
Cervical Cancer Candidate Outshines Keytruda
Iovance released new interim data from clinical studies of its tumor-infiltrating lymphocyte, or TIL, therapy LN-145 in patients with advanced cervical cancer. The company reported an objective response rate, or ORR, of 44 percent, and a disease control rate of 89 percent. Merck & Co., Inc. (NYSE: MRK)'s Keytruda, which was used as a reference, showed a 14-percent ORR.
TIL is a type of adoptive cell therapy in which the tumor-fighting T-cells are extracted from the patient's body, multiplied outside and reintroduced into the body to fight the tumor.
The mean patient age was 47 and study participants had undergone a mean of 2.6 prior lines of therapy.
"The interim data from LN-145 present compelling evidence that TIL therapy, provided as a single administration, could improve upon current treatments," Amir Jazaeri, a study investigator, said in a statement.
Melanoma Therapy Holds Up In Heavily Pretreated Population
Updated results from Cohort 2 in the ongoing innovaTIL-01 study of lifileucel in advanced melanoma showed an ORR of 38 percent and a disease control rate of 76 percent in 55 consecutively dosed post-PD-1 patients, Iovance said.
The patients were heavily pretreated, with a mean of 3.1 lines of prior therapy, including anti-PD-1, and had a high baseline tumor burden.
"At 7.4-month median follow-up, responses were maintained in the majority of patients," the company said.
First Patient Dosed In Midstage Melanoma Trial
Iovance also said the first melanoma patient in the Phase 2 IOV-COM-202 study has been dosed — the first instance of a patient naïve to checkpoint inhibitor treatment receiving the company's TIL therapy in combination with Keytruda.
The company also said it has entered into a collaboration with Genocea Biosciences Inc (NASDAQ: GNCA) to evaluate its ATLAS platform.
At last check, Iovance shares were jumping 30.72 percent to $14.68.
Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
Johnson & Johnson Analysts Laud Accelerating Pharma Business
See more from Benzinga
- The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
- The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.